The effectiveness of rituximab in treating pemphigus vulgaris by reducing anti-desmoglein (DSG) antibodies highlights the pivotal role of DSG-specific B cells in the disease (119, 120). The gene discussed is DSG1; the disease is pemphigus vulgaris.